Binding of permixon, a new treatment for prostatic benign hyperplasia, to the cytosolic androgen receptor in the rat prostate
โ Scribed by E. Carilla; M. Briley; F. Fauran; Ch. Sultan; C. Duvilliers
- Book ID
- 116004260
- Publisher
- Elsevier Science
- Year
- 1984
- Tongue
- English
- Weight
- 237 KB
- Volume
- 20
- Category
- Article
- ISSN
- 0022-4731
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
## Background: The n-hexane lipido-sterol extract of serenoa repens (lsesr, permixon, pierre fabre medicament, castres, france), a phytotherapeutic agent used in the treatment of benign prostatic hyperplasia (bph), has a multisite mechanism of action including inhibition of types 1 and 2 5alpha-red
BACKGROUND. Controversy regarding the relative efficacy of treatments for the relief of the symptoms of benign prostatic hyperplasia (BPH). METHODS. This was a 6-month double-blind randomized equivalence study that compared the effects of a plant extract (320 mg Permixon") with those of a 5a-reducta